Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.41 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the company's performance. They emphasized their commitment to long-term goals without providing specific guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company remains focused on its long-term strategy despite the current challenges.
Crinetics Pharmaceuticals reported a significant loss per share, which contributed to a 1.78% decline in its stock price. The lack of revenue figures and guidance may have raised concerns among investors about the company's short-term outlook. Overall, the market reaction reflects uncertainty regarding Crinetics' current financial health and future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANK NOVA SCOTIA
Aug 28, 2018